Efficacy and tolerability of PROMUS Element Plus everolimus-eluting platinum-chromium coronary stent vs OMEGA platinum bare metal stent in patients with acute myocardial infarction: the HORIZONS II AMI trial.

Trial Profile

Efficacy and tolerability of PROMUS Element Plus everolimus-eluting platinum-chromium coronary stent vs OMEGA platinum bare metal stent in patients with acute myocardial infarction: the HORIZONS II AMI trial.

Recruiting
Phase of Trial: Phase III

Latest Information Update: 26 Mar 2013

At a glance

  • Drugs Everolimus (Primary) ; Clopidogrel; Prasugrel
  • Indications Coronary artery restenosis; Myocardial infarction
  • Focus Registrational; Therapeutic Use
  • Acronyms HORIZONS-II-AMI
  • Most Recent Events

    • 26 Mar 2013 Status changed from planning to recruiting, as reported in a Cardiovascular Research Foundation media release.
    • 28 Mar 2012 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top